Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | RARA | P10276 | 2/20 | 0.54 |
| ▸ | RARB | P10826 | 2/20 | 0.54 |
| ▸ | RARG | P13631 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | DNM1L | O00429 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146780 | 0.88 | RARA (0.53) | ALDH1A1HTTNPSR1SMN1; SMN2TDP1 | |
| SCHEMBL1873626 | 0.87 | RARA (0.52) | ALDH1A1HTTNPSR1SMN1; SMN2TDP1 | |
| SCHEMBL1146444 | 0.87 | RARA (0.52) | ALDH1A1HTTNPSR1SMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL1169985 | 0.87 | RARA (0.52) | ALDH1A1HTTNPSR1SMN1; SMN2TDP1 | |
| SCHEMBL9909666 | 0.86 | ALDH1A1 (0.54) | ALDH1A1HTTNPSR1SMN1; SMN2TDP1 | |
| SCHEMBL19051366 | 0.83 | AR (0.74) | ALDH1A1HTTNPSR1SMN1; SMN2TDP1 | |
| SCHEMBL1146899 | 0.81 | CKS1B (0.50) | ALDH1A1SMN1; SMN2RARARARBRARG | |
| SCHEMBL1935470 | 0.77 | CHEK1 (0.52) | ALDH1A1HTTNPSR1SMN1; SMN2ALOX5 | |
| SCHEMBL27648946 | 0.76 | DHODH (0.48) | ALDH1A1HTTNPSR1SMN1; SMN2ALOX5 | |
| SCHEMBL13239090 | 0.75 | RARA (0.68) | ALDH1A1HTTNPSR1SMN1; SMN2RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334867-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170166538-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-06-15 | — | — | US | disclosed |
| US-9428517-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2016-08-30 | — | — | US | disclosed |
| US-20160068539-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2016-03-10 | — | — | US | disclosed |
| US-9200006-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2015-12-01 | — | — | US | disclosed |
| US-20140221654-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2014-08-07 | — | — | US | disclosed |
| US-8735395-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2014-05-27 | — | — | US | disclosed |
| US-20130231349-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2013-09-05 | — | — | US | disclosed |
| US-8466158-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-8426421-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2013-04-23 | — | — | US | disclosed |
| US-20120289519-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2012-08-30 | — | — | US | disclosed |
| US-8242119-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2012-08-14 | — | — | US | disclosed |
| US-8198283-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2012-06-12 | — | — | US | disclosed |
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-05 | — | — | US | disclosed |
| US-20110039862-A1 | Protease Inhibitors | MEDIVIR AB (SE) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289519-A1 | PROTEASE INHIBITORS | F2RL1, F2RL3, PREP | ALDH1A1 1507/4885HTT 2619/4885NPSR1 1120/4885 |
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | ALDH1A1 3386/4885HTT 2591/4885NPSR1 2421/4885 |
| US-20160068539-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | ALDH1A1 3140/4885HTT 2474/4885NPSR1 444/4885 |
| US-20170334867-A1 | PROTEASE INHIBITORS | CTSK, MMP26, MMP3 | ALDH1A1 3144/4885HTT 2360/4885NPSR1 703/4885 |
| US-20110039862-A1 | Protease Inhibitors | CTSK, CTSF, CTSS | ALDH1A1 3165/4885HTT 2465/4885NPSR1 446/4885 |
| US-20170166538-A1 | PROTEASE INHIBITORS | MMP8, CTSK, CTSS | ALDH1A1 3184/4885HTT 2752/4885NPSR1 414/4885 |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | ALDH1A1 3386/4885HTT 2591/4885NPSR1 2421/4885 |
| US-20130231349-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | ALDH1A1 3165/4885HTT 2465/4885NPSR1 446/4885 |
| US-20140221654-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | ALDH1A1 3140/4885HTT 2474/4885NPSR1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.